Has the French Pharma Industry valuation changed over the past few years?

Investors are optimistic on the French Pharmaceuticals industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 24.1x which is higher than its 3-year average PE of 20.8x. The 3-year average PS ratio of 2.3x is higher than the industry's current PS ratio of 1.9x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 21 Sep 2026	€105.5b	€56.5b	€4.4b	16.7x	24.1x	1.9x
Wed, 19 Aug 2026	€110.7b	€56.5b	€4.4b	18.3x	25.4x	2x
Fri, 17 Jul 2026	€109.6b	€54.6b	€5.3b	18.1x	20.7x	2x
Sun, 14 Jun 2026	€109.3b	€54.6b	€5.3b	19x	20.6x	2x
Tue, 12 May 2026	€105.8b	€54.6b	€5.3b	18.2x	20x	1.9x
Thu, 09 Apr 2026	€115.5b	€54.0b	€5.4b	19.8x	21.4x	2.1x
Sat, 07 Mar 2026	€109.9b	€54.0b	€5.4b	21.8x	20.4x	2x
Mon, 02 Feb 2026	€111.7b	€53.8b	€5.5b	22.1x	20.4x	2.1x
Wed, 31 Dec 2025	€115.5b	€53.0b	€7.0b	21.8x	16.6x	2.2x
Fri, 28 Nov 2025	€119.5b	€53.0b	€7.0b	22.8x	17.2x	2.3x
Sun, 26 Oct 2025	€122.8b	€53.0b	€7.0b	22.4x	17.6x	2.3x
Tue, 23 Sep 2025	€111.5b	€52.8b	€6.9b	19.8x	16.1x	2.1x
Thu, 21 Aug 2025	€120.1b	€52.8b	€6.9b	19.7x	17.3x	2.3x
Sat, 19 Jul 2025	€114.6b	€52.1b	€6.7b	20.4x	17.2x	2.2x
Mon, 16 Jun 2025	€118.5b	€52.1b	€6.7b	18.3x	17.8x	2.3x
Wed, 14 May 2025	€121.9b	€52.1b	€6.7b	17.7x	18.3x	2.3x
Fri, 11 Apr 2025	€120.7b	€51.2b	€5.9b	17.5x	20.3x	2.4x
Sun, 09 Mar 2025	€150.6b	€51.1b	€5.9b	18.4x	25.4x	2.9x
Tue, 04 Feb 2025	€144.4b	€51.1b	€6.3b	18.8x	23x	2.8x
Thu, 02 Jan 2025	€130.9b	€55.2b	€5.1b	18.8x	25.7x	2.4x
Sat, 30 Nov 2024	€128.9b	€55.2b	€5.1b	19.5x	25.3x	2.3x
Mon, 28 Oct 2024	€139.8b	€55.2b	€5.1b	21.1x	27.4x	2.5x
Wed, 25 Sep 2024	€144.4b	€53.9b	€4.8b	21.4x	30.1x	2.7x
Fri, 23 Aug 2024	€137.9b	€53.8b	€4.8b	20.4x	28.7x	2.6x
Sun, 21 Jul 2024	€129.5b	€52.9b	€5.2b	21.2x	25x	2.4x
Tue, 18 Jun 2024	€124.4b	€52.9b	€5.2b	20.7x	24.1x	2.4x
Thu, 16 May 2024	€128.4b	€52.9b	€5.2b	21.3x	24.8x	2.4x
Sat, 13 Apr 2024	€122.1b	€52.7b	€6.0b	20x	20.2x	2.3x
Mon, 11 Mar 2024	€123.1b	€52.6b	€6.0b	20.3x	20.4x	2.3x
Wed, 07 Feb 2024	€123.4b	€53.0b	€6.1b	20.7x	20.4x	2.3x
Fri, 05 Jan 2024	€130.9b	€52.2b	€9.7b	18.4x	13.5x	2.5x
Sun, 03 Dec 2023	€120.8b	€52.2b	€9.7b	17.7x	12.4x	2.3x
Tue, 31 Oct 2023	€119.2b	€52.2b	€9.7b	15.3x	12.3x	2.3x
Thu, 28 Sep 2023	€142.6b	€52.6b	€9.3b	18.3x	15.4x	2.7x


FR Market	-1.30%
Healthcare	-2.15%
Pharma	-1.95%
Pharma	-1.95%

	Company	Last Price	7D	1Y	Valuation
	ALTHX THX Pharma Société Anonyme	€3.43	2.7% +€1.2m	44.1%	PS58.7x
	ALDVI Advicenne	€0.87	1.9% +€232.8k	-32.3%	PE293x

Announcement • Sep 19

Ipsen Announces Board and Committee Changes

Ipsen announced the co-optation of Mariette Finet as a Director to its Board of Directors, effective September 18, 2026. Mariette Finet succeeded Michèle Ollier, who resigned from her position as Director on August 1, 2026. Mariette Finet is a Doctor of Medicine and graduate of the University of Nancy. She brings more than 35 years of experience across the healthcare, pharmaceutical and life sciences sectors. Mariette Finet began her career in the Medical Department of Laboratoires Beaufour in Paris, where she held positions in pharmaceutical asset analysis and conducted clinical research across several therapeutic areas, with a particular focus on gastroenterology. She subsequently joined Beaufour-Ipsen Pharma and later Ipsen, where she held positions in the Marketing Department. Since 2007, Mariette Finet has served in scientific and medical advisory roles at Mayroy and Highrock S.àr.l., providing expertise in investment analysis and portfolio oversight, with a particular focus on pharmaceutical, MedTech and life sciences sectors. She also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd. The Board of Directors also appointed Mariette Finet to the Board Portfolio Committee, succeeding Michèle Ollier. Mariette Finet’s appointment will be submitted for ratification at the next Annual Shareholders’ Meeting. Subject to ratification, she will serve for the remainder of Michèle Ollier’s term, which expires at the Annual Shareholders’ Meeting convened to approve the financial statements for the year ending December 31, 2026.

French (CAC) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Virbac SA (EPA:VIRP) Just Released Its First-Quarter Earnings: Here's What Analysts Think

New major risk - Revenue and earnings growth

Ipsen Announces Board and Committee Changes

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Sanofi Opens C$925 Million Flu Vaccine Facility in Toronto, Largest in Canadian History

New minor risk - Market cap size

MedinCell Names Edna Venneker as Chief Medical Officer to Lead Drug Development Initiatives

New major risk - Share price stability

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €14.200003 million.